

Prescribing of Bazedoxifene plus conjugated oestrogens (Duavive®) for post-menopausal symptoms in women with a uterus is not supported

Thurrock CCG and Basildon and Brentwood CCG do not support the prescribing of Bazedoxifene plus conjugated oestrogens (Duavive®) for the treatment of post-menopausal symptoms in women with a uterus.

Bazedoxifene acetate is a third generation selective oestrogen receptor modulator (SERM), similar to raloxifene, and has oestrogen-receptor agonist effects on bone, and antagonist effects on uterine and breast tissue. When a SERM is paired with an oestrogen, it forms a tissue-selective estrogen complex (TSEC); a novel class of therapeutic agents, which achieves an optimal blend of oestrogen receptor agonist and antagonist effects for the treatment of menopausal symptoms and prevention of osteoporosis.

The East of England Priorities Advisory Committee has advised that routine commissioning of bazedoxifene plus conjugated oestrogens (Duavive®) for the treatment of post-menopausal symptoms in women with a uterus is currently **NOT** recommended because:

- There is insufficient evidence to quantify the risks and benefits compared to current alternative treatments.
- There are no long term safety data.
- Information on cost effectiveness and cost impact is not currently available.

The full evidence review can be found here <https://www.prescqipp.info/resources/category/328-bazedoxifene-plus-conjugated-oestrogens>

Providers commissioned to provide services on behalf of Thurrock CCG and Basildon and Brentwood CCG are reminded that they are required to follow the local joint formulary and prescribing guidance, or relevant Medicines Management agreement.

Position Statement No.	3
Title	Prescribing of Bazedoxifene plus conjugated oestrogens (Duavive®) for post-menopausal symptoms in women with a uterus is not supported
References	East of England Priorities Advisory Committee - Full evidence review for Bazedoxifene plus conjugated oestrogens. https://www.prescqipp.info/resources/category/328-bazedoxifene-plus-conjugated-oestrogens
Acknowledgements	Mid Essex CCG
Version	1
Author	Medicines Management Team
Approved by	Basildon and Brentwood CCG: Prescribing Subgroup, Patient Quality and Safety Committee, Board Thurrock CCG: Medicines Management and Safety Group, Patient Quality and Safety Committee, Transformation and Sustainability Committee, Board
Date Approved	March 2017
Review Date	March 2019